ArticlePediatrics2014
Pediatric anthrax clinical management.
Article in Pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review.Health securityPooled it
- Omadacycline is activeAntimicrobial agents and chemotherapy · 2024Article
- Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- CDC Guidelines for the Prevention and Treatment of Anthrax, 2023.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2023Article
- Clinical and CT diagnosis of 50 cases ofQuantitative imaging in medicine and surgery · 2023Article
- Risk Factors for Severe Cutaneous Anthrax in a Retrospective Case Series and Use of a Clinical Algorithm to Identify Likely Meningitis and Evaluate Treatment Outcomes, Kyrgyz Republic, 2005-2012.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Responding to the Threat Posed by Anthrax: Updated Evidence to Improve Preparedness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Safety of Antimicrobials for Postexposure Prophylaxis and Treatment of Anthrax: A Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Review
- Building Children's Preparedness Capacity at the Centers for Disease Control and Prevention One Event at a Time, 2009-2018.American journal of public health · 2019Article
- Planning Considerations for State, Local, Tribal, and Territorial Partners to Receive Medical Countermeasures From CDC's Strategic National Stockpile During a Public Health Emergency.American journal of public health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Anthrax is a zoonotic disease caused by Bacillus anthracis, which has multiple routes of infection in humans, manifesting in different initial presentations of disease. Because B anthracis has the potential to be used as a biological weapon and can rapidly progress to systemic anthrax with high mortality in those who are exposed and untreated, clinical guidance that can be quickly implemented must be in place before any intentional release of the agent. This document provides clinical guidance for the prophylaxis and treatment of neonates, infants, children, adolescents, and young adults up to the age of 21 (referred to as "children") in the event of a deliberate B anthracis release and offers guidance in areas where the unique characteristics of children dictate a different clinical recommendation from adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.